Annovis Bio, Inc. Current Assets
Annovis Bio, Inc. (ANVS) had Current Assets of $7.81 million as of 2024-03-31, per its 10-Q filed 2024-05-10.
Discontinued › Balance Sheet › Assets › Assets, Current
us-gaap:AssetsCurrent · last filed 2024-05-10
- 2024-03-31: Assets, Current $7.81M.
- 2023-12-31: Assets, Current $10.21M.
- 2023-09-30: Assets, Current $10.22M.
- 2023-06-30: Assets, Current $22.82M.
| Period end | Assets, Current | Assets, Current as first filed |
|---|---|---|
| 2024-03-31 | $7.81M 10-Q · filed 2024-05-10 | |
| 2023-12-31 | $10.21M 10-Q · filed 2024-05-10 | |
| 2023-09-30 | $10.22M 10-Q · filed 2023-11-08 | |
| 2023-06-30 | $22.82M 10-Q · filed 2023-08-14 | |
| 2023-03-31 | $25.55M 10-Q · filed 2023-05-10 | |
| 2022-12-31 | $36.02M 10-K · filed 2024-03-29 | |
| 2022-09-30 | $37.12M 10-Q · filed 2023-11-08 | $32.49M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $39.97M 10-Q · filed 2023-08-14 | $36.53M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $44.10M 10-Q · filed 2023-05-10 | $43.30M 10-Q · filed 2022-05-04 |
| 2021-12-31 | $46.00M 10-K · filed 2023-03-31 | |
| 2021-09-30 | $47.65M 10-Q · filed 2021-11-03 | |
| 2021-06-30 | $49.50M 10-Q · filed 2021-07-28 | |
| 2021-03-31 | $5.96M 10-Q · filed 2021-05-06 | |
| 2020-12-31 | $8.12M 10-K · filed 2022-03-02 | |
| 2020-09-30 | $9.40M 10-Q · filed 2020-11-04 | |
| 2020-06-30 | $10.20M 10-Q · filed 2020-07-29 | |
| 2020-03-31 | $11.44M 10-Q · filed 2020-05-05 | |
| 2019-12-31 | $747.51K 10-K · filed 2021-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |